Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in
advanced solid malignancies and to further investigate CT7001 as monotherapy or in
combination with standard therapy in specific participant groups with Triple Negative Breast
Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant
for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2
negative (HER2-ve) breast cancer.